Yousif Capital Management LLC Grows Stake in ADMA Biologics Inc $ADMA

Yousif Capital Management LLC lifted its position in ADMA Biologics Inc (NASDAQ:ADMA) by 2.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 91,095 shares of the biotechnology company’s stock after buying an additional 1,837 shares during the period. Yousif Capital Management LLC’s holdings in ADMA Biologics were worth $1,659,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Allspring Global Investments Holdings LLC boosted its stake in shares of ADMA Biologics by 8.9% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 3,320,251 shares of the biotechnology company’s stock worth $59,366,000 after buying an additional 271,305 shares during the last quarter. Concurrent Investment Advisors LLC lifted its position in ADMA Biologics by 9.6% during the second quarter. Concurrent Investment Advisors LLC now owns 11,095 shares of the biotechnology company’s stock valued at $202,000 after purchasing an additional 973 shares in the last quarter. Inspire Investing LLC lifted its position in ADMA Biologics by 21.5% during the second quarter. Inspire Investing LLC now owns 21,182 shares of the biotechnology company’s stock valued at $386,000 after purchasing an additional 3,742 shares in the last quarter. Aberdeen Group plc purchased a new position in ADMA Biologics during the second quarter valued at $9,684,000. Finally, Blue Trust Inc. lifted its position in ADMA Biologics by 53.6% during the second quarter. Blue Trust Inc. now owns 2,762 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 964 shares in the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “buy (b-)” rating on shares of ADMA Biologics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the company. According to MarketBeat.com, ADMA Biologics currently has an average rating of “Buy” and an average price target of $27.67.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock opened at $14.36 on Monday. The stock’s 50-day simple moving average is $16.00 and its 200-day simple moving average is $18.36. ADMA Biologics Inc has a 52 week low of $13.50 and a 52 week high of $25.67. The company has a market capitalization of $3.43 billion, a price-to-earnings ratio of 16.70 and a beta of 0.47. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The business had revenue of $121.98 million for the quarter, compared to the consensus estimate of $121.77 million. During the same period in the previous year, the business earned $0.13 earnings per share. The business’s revenue was up 13.8% on a year-over-year basis. As a group, analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.